132 results
425
EX-99.2
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement
8-K
EX-99.2
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement
424B3
HEPA
Hepion Pharmaceuticals, Inc.
15 Jul 24
Prospectus supplement
5:17pm
, New Jersey, focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation … for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment
8-K
EX-99.1
vdgn95lz40x20 97s
7 Dec 23
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
8:41am
8-K
EX-99.1
sg26qvg1846mu1ultag
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
424B5
22cwsxfb69ijg r6
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-99.1
fve3g2fxzeim yer1js
24 Jul 23
Regulation FD Disclosure
4:04pm
424B5
8q3bao88c8bk
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.1
vyxwr cfq3porm15gu9
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.2
tdempu1k
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
lck6k798obxh48vkq
10 May 23
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
5:17pm